JP2015511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511632A5
JP2015511632A5 JP2015502543A JP2015502543A JP2015511632A5 JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5 JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5
Authority
JP
Japan
Prior art keywords
melanoma
trifluoromethyl
amino
treatment
raf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052556 external-priority patent/WO2013144923A1/en
Publication of JP2015511632A publication Critical patent/JP2015511632A/ja
Publication of JP2015511632A5 publication Critical patent/JP2015511632A5/ja
Pending legal-status Critical Current

Links

JP2015502543A 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Pending JP2015511632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2015511632A JP2015511632A (ja) 2015-04-20
JP2015511632A5 true JP2015511632A5 (https=) 2016-06-02

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502543A Pending JP2015511632A (ja) 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Country Status (6)

Country Link
US (1) US20150126533A1 (https=)
EP (1) EP2830664A1 (https=)
JP (1) JP2015511632A (https=)
CN (1) CN104428001A (https=)
CA (1) CA2868954A1 (https=)
WO (1) WO2013144923A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010564A2 (pt) * 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CN107405348B (zh) * 2014-12-23 2021-06-11 点疗法-1公司 Raf抑制剂与紫杉烷的组合
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
JP7707166B2 (ja) * 2019-11-27 2025-07-14 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド Ｐａｎ－ｒａｆキナーゼインヒビターの固体分散物
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合
MX2023009642A (es) * 2021-02-19 2023-10-16 Day One Biopharmaceuticals Inc Combinacion de inhibidor de raf e inhibidor de mek.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
HUE067723T2 (hu) * 2009-10-16 2024-11-28 Novartis Ag MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
JP2015511632A5 (https=)
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
JP2012530705A5 (https=)
EP3641754A4 (en) COMPOSITIONS AND TREATMENTS AGAINST SLEEP DISORDERS
NZ604831A (en) Apoptosis signal-regulating kinase inhibitors
NO2017023I1 (no) Venetoklaks, dvs. 4-(4-{[2-(4-klorfenyl)-4,4-dimetylsykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4[{tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
JP2011513196A5 (https=)
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
JP2014524362A5 (https=)
JP2014062126A5 (https=)
JP2015533163A5 (https=)
PT2684877T (pt) Sal farmaceuticamente aceitável de (e)-n-[4-[[3-cloro-4-(2- piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2r)-1-metilpirrolidin-2-il]prop-2-enamida, seu método de preparação e a sua utilização clínica
JP2016529004A5 (https=)
JP2016528011A5 (https=)
SMT202100279T1 (it) N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamide emiidrato a base libera, metodi di fabbricazione e usi di esso
JP2016020375A5 (https=)
JP2013538856A5 (https=)
JP2016539174A5 (https=)
PL3544977T3 (pl) Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
JP2012528824A5 (https=)
EP3643708C0 (en) 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPH, ITS PREPARATION PROCESS AND APPLICATION
JP2015509917A5 (https=)